Angioedemas

In addition to its approved commercial use, DX-88 is also being evaluated for its therapeutic potential in other angioedema indications (acquired and ACE inhibitor-induced angioedemas) and, through a collaboration with Fovea Pharmaceuticals (a subsidiary of sanofi aventis), is in a Phase 1 trial for retinal vein occlusion-induced macular edema. ❋ Unknown (2010)

This four part strategy includes; first, Dyax's US commercialization of DX-88 in HAE, second the finalization of a European partnership for DX-88 in angioedemas, third DX-88's development and commercialization in surgical indications through our partnership with Cubist Pharmaceuticals, and finally the development of DX-88 in additional angioedemas, including nonhereditary angioedemas. ❋ Unknown (2008)

I think, other areas that we are still under active discussion and seeking input from experts in the field include that broad area of idiopathic angioedemas and here I am not talking about the allergic (inaudible) histamine of phenomenon but the ones that relate to a kallikrein pathway. ❋ Unknown (2008)

As we reported at the end of the quarter, while the exclusive negotiation period with Dompe for European partnership in DX-88 and angioedemas ended on September 30. ❋ Unknown (2008)

With respect to DX-88 in other angioedemas, we are pleased to announce the institutional review board approval was recently received for compassionate use of DX-88 in a study of patients with acquired angioedema. ❋ Unknown (2008)

(acquired and ACE inhibitor-induced angioedemas) and, through a collaboration with Fovea ❋ Unknown (2010)